FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For Herceptin Treatment

The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue…

APP Pharmaceuticals To Market Letrozole Tablets, USP In The U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE: FKONCO) (BSE: 532545)…

After Breast Cancer Treatment, Study Finds Breast-Feeding Safe

Women who have survived breast cancer should not be denied the opportunity to breast-feed their children, say researchers who presented the results of a new study at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy…

Genomic Health Launches "Pass It On… Until Every Woman Knows," To Educate People About Personalized Breast Cancer Treatment And Oncotype DX

Genomic Health, Inc. (NASDAQ: GHDX) announced the launch of an online campaign, Pass It On… Until Every Woman Knows, to educate people about personalized breast cancer treatment and the Oncotype DX® breast cancer test…

Surgeons Impact Whether A Woman Gets Breast Reconstruction

When breast cancer surgeons regularly confer with plastic surgeons prior to surgery, their patients are more likely to have reconstruction, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center. Where a woman goes for breast cancer treatment can vary widely – ranging from small private practices to large hospital settings…

Next Page »